NCT07230171
The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 16 words Show 7 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Jun 30, 2027 to Jun 14, 2026
- Study completion date changed from estimate of Aug 31, 2027 to Aug 30, 2026
- Secondary endpoints: 12 to 10
- Site details revised
- Collaborators: 2 to 5
- Publications: details revised at 1 of 1 entry
- Notable Primary endpoint(s) modified
- Enrollment reduced: 106 → 92 participants
- Secondary endpoints: 11 to 12
- Notable Enrollment target: 400 to 106
- Eligibility criteria shortened, about 15 words
- Secondary endpoints: 9 to 11
- Collaborators expanded, about 7 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in the mean pain intensity
Timeframe: At the week 1.
Secondary (10)
Average pain intensity
Proportion of patients achieving pain reduction at 50%;
The median pain relief time
The Revised FM Impact Questionnaire (FIQR)
Hospital Anxiety and Depression scale (HADS)
Show 5 moreShow less
The short-form 36 Health Survey (SF-36)
Multidimensional Fatigue Inventory (MFI)
Medical Outcomes Study Sleep Scale (MOS)
The doses of pregabalin and venlafaxine
Adverse events
Arms and interventions
Control groupActive comparator
Pregabalin and venlafaxine concomitant therapy
Treatment groupExperimental
Esketamine plus pregabalin and venlafaxine concomitant therapy
Drugs: Pregabalin and venlafaxine concomitant therapy, Esketamine plus pregabalin and venlafaxine concomitant therapy
Sites
1 site in 1 country
- Beijing Tiantan Hospital, Beijing, Beijing 100070Beijing, China